ClinicalTrials.gg
CompletedNCT00501969Updated Oct 2, 2014Results posted

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease

A Phase 3 interventional study of Rotigotine in Advanced Stage Parkinson's Disease, sponsored by UCB Pharma. Completed at 53 sites in 17 countries. Open to participants aged 31 Years and older. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
395
Allocation
Not applicable
Ages
31 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
4th of 42
395 · median 123
Started
2004
with 4 others
Phase 3
20 of 44
none open now
Registered
8th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 4th largest by enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2004, is one of 20 in phase 3, and was the 8th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 31 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with advanced-stage idiopathic Parkinson's disease

Read the detailed description

This is the open-label extension to the randomized, double-blind, placebo-and active controlled SP515 (NCT00244387) trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease that were not well-controlled on levodopa

03

Conditions studied

  • Advanced Stage Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • Neupro®
04

Who can participate

Ages eligible
31 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have completed four months of maintenance treatment in the SP515 (NCT00244387) double-blind trial

Exclusion criteria

Exclusion Criteria:

  • Subjects who had an ongoing serious adverse event from SP515 (NCT00244387) double-blind trial that was assessed as related to study medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
395 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Rotigotine

    Drug: Rotigotine

Interventions

  • Rotigotine trans-dermal patches once daily: 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)

    Also known as: Neupro®

06

What researchers measure

Primary outcomes

  1. Number of Subjects With at Least One Adverse Event During This Open-label Extension Study

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: five years

Secondary outcomes

  1. Number of Subjects Who Withdrew From the Trial Due to an Adverse Event

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: five years

  2. Mean Epworth Sleepiness Scale Score During the Open-label Extension

    The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.

    Time frame: Visit 13 (end of year 1), Visit 17 (end of year 2), Visit 21 (end of year 3), Visit 25(end of year 4)

07

Results

Posted Jan 12, 2010

Participant flow

An Open-Label Extension to the Double-Blind SP515 (NCT00244387) Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects with Advanced-Stage Idiopathic Parkinson's Disease who are not well controlled on L-Dopa from August 2004 to December 2008

Participant flow — Overall Study
MilestoneRotigotine
Started395
Completed189
Not completed206
Withdrew: Major protocol violation4
Withdrew: Lack of efficacy29
Withdrew: Adverse event76
Withdrew: Unsatisfactory compliance of subject7
Withdrew: Subject withdrew consent51
Withdrew: Lost to follow-up4
Withdrew: Other: tired of clinical trial process1
Withdrew: Other: sponsors request10
Withdrew: Other: sponsor termination at site1
Withdrew: Other: sponsor stopped study12
Withdrew: Other: severe dementia unable sign pic1
Withdrew: Other: patients + investigator agreement1
Withdrew: Other: patient is going to have dbs1
Withdrew: Other: pat pending surgery for pd1
Withdrew: Other: dx changed - parkinsons to psnp1
Withdrew: Other: as required by local ec2
Withdrew: Other: admin request from the sponsor3
Withdrew: Other: sponsor termination/commercial rx1

Outcome measures

PrimaryNumber of Subjects With at Least One Adverse Event During This Open-label Extension Study

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
five years
Reported as:
Number · Subjects
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study
SubjectsRotigotine
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study357
SecondaryNumber of Subjects Who Withdrew From the Trial Due to an Adverse Event

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
five years
Reported as:
Number · Subjects
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event
SubjectsRotigotine
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event76
SecondaryMean Epworth Sleepiness Scale Score During the Open-label Extension

The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.

Time frame:
Visit 13 (end of year 1), Visit 17 (end of year 2), Visit 21 (end of year 3), Visit 25(end of year 4)
Reported as:
Mean · Score on a scale
Mean Epworth Sleepiness Scale Score During the Open-label Extension
Score on a scaleRotigotine
Visit 13 (end of year 1) (n=377)7.4 ± 4.7
Visit 17 (end of year 2) (n=377)7.8 ± 5.1
Visit 21 (end of year 3) (n=377)8.0 ± 5.1
Visit 25 (end of year 4) (n=377)8.3 ± 5.2

Adverse events

Collected over Up to five years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—148/395 (37.5%)305/395 (77.2%)
Most frequent serious events
Showing 10 of 158
Most frequent serious events
EventRotigotine
Parkinson's diseaseNervous system disorders18/395
PneumoniaInfections and infestations7/395
Urinary retentionRenal and urinary disorders6/395
Urinary tract infectionInfections and infestations5/395
Cardiac failureCardiac disorders4/395
FallInjury, poisoning and procedural complications4/395
OsteoarthritisMusculoskeletal and connective tissue disorders4/395
ArthralgiaMusculoskeletal and connective tissue disorders4/395
ParkinsonismNervous system disorders4/395
HallucinationPsychiatric disorders4/395
Most frequent other events
Showing 10 of 24
Most frequent other events
EventRotigotine
SomnolenceNervous system disorders133/395
FallInjury, poisoning and procedural complications61/395
DyskinesiaNervous system disorders55/395
NauseaGastrointestinal disorders54/395
Back painMusculoskeletal and connective tissue disorders48/395
InsomniaPsychiatric disorders45/395
Parkinson's diseaseNervous system disorders44/395
Weight decreasedInvestigations43/395
Application site erythemaGeneral disorders40/395
Application site pruritusGeneral disorders38/395

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rotigotine
<=18 years0
Between 18 and 65 years183
>=65 years212
Age, Continuous
Age, Continuous(years)Rotigotine
Mean64.4 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine
Female144
Male251
Region of Enrollment
Region of Enrollment(participants)Rotigotine
Finland8
Spain35
Austria6
Israel22
United Kingdom10
Italy33
France9
Czech Republic50
Hungary11
Poland65
Croatia27
Australia30
South Africa52
Germany4
Norway8
New Zealand16
Sweden9
08

Study locations

53 sites
  • Bedford Park, Australia
  • Concord, Australia
  • Darlinghurst, Australia
  • East Gosford, Australia
  • Westmead, Australia
  • Innsbruck, Austria
  • Zagreb, Croatia
  • Brno, Czech Republic
  • Ostrava - Poruba, Czech Republic
  • Pardubice, Czech Republic
  • Plzen, Czech Republic
  • Praha, Czech Republic
  • Oulu, Finland
  • Pori, Finland
  • Aix-en -Provence, France
  • Lille cedex, France
  • Lyon, France
  • Aachen, Germany
  • Bochum, Germany
  • Budapest, Hungary
  • Miskolc, Hungary
  • Pecs, Hungary
  • Petach-Tikva, Israel
  • Tel Aviv, Israel
  • Milano, Italy
  • Napoli, Italy
  • Padova, Italy
  • Pisa, Italy
  • Pozzilli, Italy
  • Roma, Italy
  • Auckland, New Zealand
  • Christchurch, New Zealand
  • Wellington, New Zealand
  • Bergen, Norway
  • Stavanger, Norway
  • Tonsberg, Norway
  • Trondheim, Norway
  • Gdansk, Poland
  • Krakow, Poland
  • Lublin, Poland
  • Mosina k/Poznania, Poland
  • Olsztyn, Poland
  • Warszawa, Poland
  • Cape Town, South Africa
  • Pretoria, South Africa
  • Tygerberg, South Africa
  • Barcelona, Spain
  • Madrid, Spain
  • San Sebastian, Spain
  • Stockholm, Sweden
  • Blackpool, United Kingdom
  • Glasgow, United Kingdom
  • Sheffield, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2007
First posted
Jul 17, 2007
Start
Aug 2004
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Jan 12, 2010
Last update
Oct 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00501969
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jul 17, 2007
Start date
Aug 2004
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Jan 12, 2010
Last update
Oct 2, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion